Investor Presentaiton

Immunology LPA₁ Sotyktu CD19 NEX T Sjögren's Syndrome Phase 3 study (POETYK-SjS-11) Inclusion Criteria: Meet 2016 ACR/EULAR criteria with disease duration ≤7.5 yrs Anti-SSA/RO+ •⚫ ESSDAI ≥5 Primary Endpoint: ESSDAI change from baseline at Week 52 Key Secondary Endpoint: ESSPRI deucravacitinib 3 mg BID R deucravacitinib 6 mg BID 1:1:1 Placebo Ill Bristol Myers Squibb™ 1. NCT05946941 Data anticipated in 2027 Primary Endpoint Week 52 Long-term extension and follow- up Not for Product Promotional Use 66

View entire presentation